Advertisement
Australia markets closed
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • AUD/USD

    0.6487
    -0.0013 (-0.20%)
     
  • OIL

    82.69
    -0.12 (-0.14%)
     
  • GOLD

    2,339.10
    +0.70 (+0.03%)
     
  • Bitcoin AUD

    97,307.52
    -4,598.23 (-4.51%)
     
  • CMC Crypto 200

    1,351.85
    -30.72 (-2.22%)
     
  • AUD/EUR

    0.6072
    +0.0002 (+0.03%)
     
  • AUD/NZD

    1.0955
    +0.0013 (+0.12%)
     
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,064.87
    +24.49 (+0.30%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    17,894.43
    -194.27 (-1.07%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

If You Had Bought Cardiovascular Systems (NASDAQ:CSII) Stock Three Years Ago, You Could Pocket A 128% Gain Today

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Cardiovascular Systems, Inc. (NASDAQ:CSII) share price has soared 128% in the last three years. That sort of return is as solid as granite.

See our latest analysis for Cardiovascular Systems

While Cardiovascular Systems made a small profit, in the last year, we think that the market is probably more focussed on the top line growth at the moment. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. It would be hard to believe in a more profitable future without growing revenues.

ADVERTISEMENT

In the last 3 years Cardiovascular Systems saw its revenue grow at 9.8% per year. That's pretty nice growth. Broadly speaking, this solid progress may well be reflected by the healthy share price gain of 32% per year over three years. The business has made good progress on the top line, but the market is extrapolating the growth. It would be worth thinking about when profits will flow, since that milestone will attract more attention.

Depicted in the graphic below, you'll see revenue and earnings over time. If you want more detail, you can click on the chart itself.

NasdaqGS:CSII Income Statement, June 17th 2019
NasdaqGS:CSII Income Statement, June 17th 2019

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So it makes a lot of sense to check out what analysts think Cardiovascular Systems will earn in the future (free profit forecasts).

A Different Perspective

We're pleased to report that Cardiovascular Systems shareholders have received a total shareholder return of 26% over one year. That's better than the annualised return of 5.2% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.